Women authorship ‘still low’ in phase 3 trials at ASCO, but gains made

CHICAGO — Women accounted for less than 30% of first and senior authors of phase 3 solid-tumor trials presented at ASCO Annual Meeting between 2015 and 2025.Trends improved throughout the decade, according to data presented at the 2026 event, but disparities persist, particularly among non-breast cancer investigations and in trials from low- to middle-income countries.

Raccontata dahealio.com